

ASCEPT, APFP & APSA Joint Congress

1 – 4 Dec 2024 | Melbourne Convention & Exhibition Centre, Australia
ascept-apfp-apsa.com | #ascept-apfp-apsa


Supported by:



Sunday 1 December 2024

08:30 – 18:00	Registration desk open		
	Room: Goldfields Foyer		
09:00 – 11:00	WORKSHOP 1: From the benchtop to the bedside <i>ASCEPT & APSA Joint Careers Workshop</i>	WORKSHOP 2: IUPHAR Transparency & Reproducibility	WORKSHOP 3: Pharmacogenomic education: Where are we now and how can we improve?
	Room: Eureka Room 1	Room: Eureka Room 2	Room: Eureka Room 3
	Chair: Mariah Stavrou, UNSW Sydney, Lorna Pairman, University of Otago, Milan Sundermann, University of Otago and Temitope Esther, The University of Sydney	Chair/Presenter: Prof Debbie Hay and Dr Michael Garelia, University of Otago	Chair: Alison Shield, The University of Canberra and A/Prof Kellie Charles, The University of Sydney
	Presenters: Katherine Martin, Therapeutic Goods Administration, Dr Nashwa Masnoon, The University of Sydney, Dr Elva Zhao, Monash University and Dr Nilushi Karunaratne, Monash University		Building knowledge and confidence in pharmacogenomics – evaluation of a pharmacy module Sophie Stocker, The University of Sydney
			Development of an evidence-based pharmacogenomics education and implementation program for pharmacists working in cancer care Senthil Lingaratnam, Peter MacCallum Cancer Centre
			Developing and delivering genetics-focused educational resources, programs and campaigns for public and professional audiences Bronwyn Terrill, Australian Genomics and Garvan Institute of Medical Research
		Pharmacogenomic principles in the context of drug development Nuala Helsby, University of Auckland	
11:00 – 11:15	Comfort break		
11:15 – 13:15	WORKSHOP 4: Embracing diversity: cultivating awareness and understanding of different groups and cultures	WORKSHOP 5: Navigating the Valley of Threats - Bringing a potential therapeutic from candidate to the clinic	WORKSHOP 6: PSA Workshop -World Cafe: A showcase of current quality, safety and effective use of medicine research and unleashing future research opportunities
	Room: Eureka Room 1	Room: Eureka Room 2	Room: Eureka Room 3
	Chair: A/Prof Elly Djouma, La Trobe University and Brendan Wilkins, UNSW	Chair: Felicity Grzemski and Karen Scalzo-Inguanti, Novotech Cro-Melbourne	Chair: Dr Amanda Cross, Monash University
	Mirror, mirror: changing the mindset of what we see Prof Faye McMillan, University of Technology	Navigating the Valley of Threats - Bringing a potential therapeutic from candidate to the clinic.: TPP and Regulatory Strategy Orin Chisholm, The University of Sydney and PharmMed	From Concept to Implementation: The Evolution of the On-Site Pharmacist in Residential Aged Care Model A/Prof Sam Kosari, University of Canberra
	Rethinking research culture Prof Francine Marques, Monash University	Clinical strategy – considerations for Phase 1 clinical studies Karen Scalzo-Inguanti, Novotech-CRO	Utilising communities of practice and digital tools to support new aged care onsite pharmacists Adj A/Prof Amy Page, The University of Western Australia

	<p>Panel discussion: Zanfina Ademi, Monash University, A/Prof Anthony Vinh, La Trobe University, Dr Angelina Lim, Monash University, Dr Peishen (Elva) Zhao, Monash University, Dr Michael De Silva, La Trobe University and Pranav Runwal, Monash University</p>	<p>Preclinical Toxicity Testing Strategy – why, what, how Lynne Clapham, Agilex Biolabs</p>	<p>Using health informatics to transform care delivery A/Prof Magda Raban, Australian Institute of Health Innovation, Macquarie University</p>
		<p>Navigating the Valley of Threats - CMC Strategy in Bringing a Potential Therapeutic from Candidate to the Clinic Reshma Ganapathi, Novotech-CRO, Brisbane</p>	<p>Medication Advisory Committees and emerging system-level roles for pharmacists Dr Amanda Cross, Monash University</p>
		<p>Navigating the Valley of Threats - Bringing a potential therapeutic from candidate to the clinic – Are you Ready for the Clinic? Submitting to an Ethics Committee Jerneen Williams, Bellberry Limited</p>	
		<p>Navigating the Valley of Threats – Bringing it all together Prof Kevin Pflieger, Biomedical and Health Innovation, The University of Western Australia</p>	
13:15 – 13:30	Comfort break		
13:30 – 15:30	<p>WORKSHOP 7: Applying the core concepts of pharmacology to a range of professions - customising graduate outcomes to their professional needs <i>ASCEPT & APSA Joint Education Workshop</i></p>	<p>WORKSHOP 8: Advances in Microphysiological Systems (MPS): Technologies and Approaches Enabling FDA Modernisation Act Impacts on Non-animal Methods</p>	<p>WORKSHOP 9: Codesign in Medication Safety Research</p>
	Room: Eureka Room 1	Room: Eureka Room 2	Room: Eureka Room 3
	Chair: A/Prof Tina Hinton, The University of Sydney	Chair: Prof Alastair Stewart, The University of Melbourne, Dr Simon Foster, QIMR Berghofer Medical Research Institute	Chair: Dr Mouna Sawan and Dr Lisa Kouladjian O'Donnell, The University of Sydney
	<p>History and progress of the International Union of Basic and Clinical Pharmacology Education Section (IUPHAR-Ed) Core Concepts of Pharmacology (CCP) project Anna-Marie Babey, The University of New England</p>	<p>Engineering Drug Discovery and Development, Technologies Supporting the FDA Modernization Act 2.0 Prof Alastair Stewart, Asia Pacific Federation of Pharmacologists (APFP) and Centre Director of ARC CPTT, The University of Melbourne</p>	<p>Introduction and reflection exercise Dr Lisa Kouladjian O'Donnell, The University of Sydney</p>
	<p>Applying the core concepts of pharmacology to meet professional needs A/Prof Joe Nicolazzo, Monash University, A/Prof Elly Djouma, La Trobe University, A/Prof Alison Shield, University of Canberra, Dr Gregg Maynard, Charles Sturt University, Dr Marina Junqueira Santiago, Macquarie University, A/Prof Lynette Fernandes, University of Western Australia, Dr Suong Ngo, The University of Adelaide, Dr Nilushi Karunaratne, Monash University, Dr Betty Exintaris, Monash University, Dr Suzanne Caliph, Monash University, A/Prof Tamara Paravicini, RMIT University</p>	<p>Advancing MPS and Combinatorial NAMs Towards Regulatory Acceptance and Global Utility Dr Danilo Tagle, Office of Special Initiatives at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)</p>	<p>Navigating Authenticity: Considerations in Co-design Eileen McDonald, Deakin University & Mouna Sawan, The University of Sydney</p>
		<p>Receptor-Heteromer Investigation Technology in the drug development process Prof Kevin Pflieger, The University of Western Australia (UWA)</p>	<p>Panel discussion Linda Truong, The University of Newcastle, A/Prof Barbara Farrell, The University of Ottawa, Prof Michael Berk, Deakin University, Eileen McDonald, Deakin University & Mouna Sawan, The University of Sydney</p>
		<p>Engineering a Microfluidic Blood-Brain-Barrier on a Chip Model Prof Nico Voelcker, Monash University</p>	<p>Reflection exercise Dr Lisa Kouladjian O'Donnell, The University of Sydney</p>
		<p>Advanced 3D Cell Culture Platform for Recapitulating Complex Tissues Dr Chia-Chi Chen, Australian Centre for Disease Preparedness (ACDP), CSIRO</p>	
		<p>Multi-organ MPS for Applications in Drug Testing Prof Yi-Chin Toh, Queensland University of Technology</p>	


		Multiplexed Perfusion System for Physiological Emulation of Biological Cultures Dr Bryan Gao, The University of Melbourne		
		An End User Perspective of the Perfusion System: Application to Circadian Testing Jana Zielinski, The University of Melbourne		
16:00 – 16:30	Education Forum AGM	Student Forum AGM	Clinical Pharmacology SIG AGM	Pharmacogenomics SIG AGM
	Room: Eureka Room 1	Room: Eureka Room 2	Room: Eureka Room 3	Room: Hospitality Suite 6 (L1)
16:30 – 16:50				Innovation & Industry SIG AGM
				Room: Hospitality Suite 6 (L1)
17:00 – 18:30	100. Congress opening and keynote presentation 1: APFP keynote Modern Pharmacological research of traditional medicine based on treatment of diseases Prof Guanhua Du, Peking Union Medical College		Sponsored by 	
	Room: Goldfields Theatre			
	Chair: A/Prof Bridin Murnion, St Vincent's Hospital Sydney, Dr Sarira El-Den, The University of Sydney and Prof Alastair Stewart, The University of Melbourne			
18:30 – 20:00	Welcome reception			
	Room: Goldfields Event Space			

WORLD-CLASS PHARMACY AND PHARMACEUTICAL SCIENCE RESEARCH





Monash Institute of Pharmaceutical Sciences (MIPS) is a dynamic, innovative and ambitious centre of research and learning, with a growing emphasis on cutting edge global projects. More than 450 MIPS scientists research drug discovery, design, delivery and use. Our therapeutic strengths lie in neuroscience and mental health, cardiovascular and metabolic health, and global health.


Find out more monash.edu/mips



THERAPEUTIC GUIDELINES®



TRUSTED
INDEPENDENT.
CONCISE.
EVIDENCE BASED.



Join the Future of Clinical Pharmacology

Collaborate with Us • Study with Us • Work with Us

CRICOS Provider Code: 00098G



Monday 2 December 2024



07:30 – 18:00	Registration desk open			
	Room: Goldfields Foyer			
08:00 – 08:50	200. Keynote presentation 2: BPS Lecturer Making and Using Medicines better using a data science approach Prof Reecha Sofat, University of Liverpool			
	Room: Goldfields Theatre			
	Chair: A/Prof Bridin Murnion, St Vincent's Hospital Sydney			
CONCURRENT SESSION 1				
09:00 – 10:30	Oral presentations 1: Drug Discovery Theme Room: Eureka Room 1	Oral presentations 2: Pharmacy Practice & Clinical Pharmacology Themes Room: Eureka Room 2	Oral presentations 3: Cardiovascular & Urogenital & Gastrointestinal Themes Room: Eureka Room 3	Oral presentations 4: Drug Disposition and Response & Toxicology Themes Room: Courtyard Room 1&2
Chairs:	Prof Arthur Christopoulos, Monash University and Henry Purbrick, Harry Perkins Institute of Medical Research	Hana Amer, University of South Australia and Dr Paul Chin, University of Otago	Dr Simon Foster, QIMR Berghofer Medical Research Institute and Prof Donna Sellers, Bond University	Dr Katie Burns, University of Auckland and Dominika Fuhs, Monash University
09:00 – 09:15	201. HOXC12 co-ordinates b2-adrenoceptor coupling to a cAMP/calcium feedforward loop to drive invasion Terrance Lam, Monash University	207. Pharmacokinetics, dosing, and effectiveness of allopurinol in dialysis: a scoping review Noha Kamel, The University of Sydney	213. Omics and organoids: human cardiac fibrosis modelling for therapeutic target discovery Dr Harley Robinson, QIMR Berghofer Medical Research Institute	219. Does noroxycodone counter oxycodone analgesia: evidence from a clinical study Prof Andrew Somogyi, The University of Adelaide
09:15 – 09:30	202. Discovery of PDLIM7 and PTPN9 as novel β2-adrenoceptor protein interactors Shaqayeq Ramazani, Monash University	208. Reliably Quantifying Medicines Use Using Prescribing Data - Definitions Matter A/Prof Matthew Doogue, The University of Otago	214. Mechano-sensitive protein TXNDC5 promotes AVF neointimal hyperplasia through EndoMT and eNOS suppression Laura Ianalieva, National Taiwan University College of Medicine	220. Intratumoral drug metabolism: does it affect anti-cancer drug efficacy? Prof Robyn Meech, Flinders University
09:30 – 09:45	203. Tomentosol A, isolated from bee propolis, inhibits TGF-β1/SMAD3 signalling in human fibroblasts Lisa Randall, The University of the Sunshine Coast	209. Strategies to facilitate continuity of in-hospital medication changes post-discharge: a systematic review Kate Johnstone, The University of Sydney	215. The evolutionary loss of cardiac regeneration; the impact of the ectotherm-to-endotherm transition Lynn Devilee, Qimr Berghofer Medical Research Institute	221. Entry and impacts of effective cystic fibrosis drug Elexacaftor/ Tezacaftor/Ivacaftor on fetal cortex Danni Li, The University of Melbourne
09:45 – 10:00	204. Induction of S-phase arrest and apoptosis in glioblastoma via the HDAC8 PROTAC Jiranan Chotitumnavee, Mahidol University	210. A real-world analysis of AI chatbot performance for medicines information enquiries Duncan Yorkston, Health New Zealand - Te Whatu Ora Waitaha	216. Gallic acid strengthens intestinal barrier: Mechanisms of action and its anti-colitogenic application Purisha Kulworasreth, Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy	222. PAGANZ: Ceftolozane/tazobactam plus meropenem against ST235-clone Pseudomonas aeruginosa isolates in hollow-fibre infection model Siobhonne Breen, Monash University
10:00 – 10:15	205. Inhibition of CK1δ Attenuates IL-1α-Induced Epithelial-Mesenchymal Transition in Human Lung Epithelial Cells Jana Zielinski, The University of Melbourne	211. Pharmacists and community health workers to improve medication adherence: a systematic review Dr Carole Bandiera, The University of Sydney, School of Pharmacy	217. Determining the mechanisms underlying BCG-immunotherapy induced lower urinary tract side effects Georgia Bourlotos, Flinders Health and Medical Research Institute	223. Longitudinal linkage of hospitalised paracetamol poisoning in NSW using the PAVLOVA cohort Annabelle Chidiac, The University of Sydney
10:15 – 10:30	206. Exploring and Targeting Calcium Signaling Pathways in Cellular Senescence Vijayraghavan Seshadri, University of Tasmania	212. A model of shared responsibility in pharmacy practice William Olsen, The University of Queensland	218. Mucosa-innervating bladder afferents regulate urinary tract infection severity and persistence Cindy Tay, Flinders University	224. Active Learning for hERG Risk Modelling in Drug Development Dr Slade Matthews, The University of Sydney
10:30 – 11:10	Morning tea with exhibitors Poster presentations: Cardiovascular, Clinical Pharmacology, Education, Medicines for Tropical Diseases, Pharmaceutical Sciences, Pharmacoepidemiology, Respiratory & Inflammation, Traditional Medicines			
	Room: Goldfields Event Space			

CONCURRENT SESSION 2

11:15 – 13:15	Symposium 1: mRNA Therapeutics – Its complex and more than meets the eye	Symposium 2: Drug Repurposing using real-world data; perspectives from the Asia-Pacific	Symposium 3: Educating for careers – authentic learning and assessment in pharmacology and pharmaceutical science education	Symposium 4: Advancing Drug Discovery through Modern Research on Chinese Medicine and Natural Products
	Room: Eureka Room 1	Room: Eureka Room 2	Room: Eureka Room 3	Room: Courtyard Room 1 & 2
Chairs:	Prof Carl Kirkpatrick and A/Prof Cornelia Landersdorfer, Monash University	Dr Jenni Ilomaki and A/Prof Natalie Trevaskis, Monash University	Dr Chiao Xin Lim, RMIT University and A/Prof Graham Mackay, The University of Melbourne	Prof Simon Ming-Yuen Lee, The Hong Kong Polytechnic University and Prof Haifa Qiao, Shaanxi University of Chinese Medicine
11:15 – 11:45	225. Recent Advancement and Future Directions in mRNA/LNP Therapeutics Uli Frevert, Moderna	229. Bridging basic science and big data for drug repurposing research A/Prof Natalie Trevaskis, Monash University	233. What authenticity do we need in authentic assessment? Dr Joanna Tai, Deakin University	237. Resolution Pharmacology: Unveiling Nature's Healing Mechanisms Dr Chengxue Helena Qin, Monash Institute of Pharmaceutical Sciences
11:45 – 12:15	226. Developing & manufacturing Australia first mRNA Vaccine: Lessons to inform the future of mRNA medicines Dr Harry Al-Wassiti, MIPs	230. An outcome-wide approach to generate drug repurposing hypotheses using tree-based scan statistics George SQ Tan, Monash University	234. Working with actors, healthcare professionals and people with lived experience to develop and deliver simulated mental health assessments Dr Sarira El-Den, The University of Sydney	238. Therapeutic effects of tetramethylpyrazine nitron in Alzheimer's disease mouse model Prof Pui Man (Maggie) Hoi, The University of Macau
12:15 – 12:45	227. MMQPA presentation – building models to collaborate and translate mRNA therapeutics A/Prof Cornelia Landersdorfer, Monash University	231. Case studies of hypothesis validation from Taiwan Prof Edward Lai, National Cheng Kung University	235. Embedding industry-relevant skills and thinking in the Pharmacology practical class Dr Makhala Khammy, The University of Melbourne	239. Dehydroervatamine as a Promising Novel TREM2 Agonist, Attenuates Neuroinflammation Prof Ming-yuen Simon Lee, The Hong Kong Polytechnic University
12:45 – 13:15	228. Trends in Korean mRNA vaccine development: future strategy of governmental projects leading industries Prof Kevin Kee-Jong Hong, Gachon University	232. Approaches for assessing cost-effectiveness of existing medications to potential new indications A/Prof Wee Hwee Lin, National University of Singapore	236. Begin with the end in mind in pharmacology and pharmaceutical sciences Dr Maan-Yuh Lin, National Yang Ming Chiao Tung University (NYCU), Taipei, Taiwan	240. The intervention effect of Dengzhanshengmai Formula involves MALT1/NF-κB signaling pathway in regulating microglia-mediated neuroinflammation after cerebral ischemia Prof Jingjing Zhang, China Academy of Chinese Medical Sciences
13:15 – 14:10	Lunch with exhibitors Poster presentations: Cardiovascular, Clinical Pharmacology, Education, Medicines for Tropical Diseases, Pharmaceutical Sciences, Pharmacoepidemiology, Respiratory & Inflammation, Traditional Medicines			
	Room: Goldfields Event Space			

CONCURRENT SESSION 3

14:15 – 15:45	Oral presentations 5: Drug Discovery Theme	Oral presentations 6: Pharmacy Practice Theme	Oral presentations 7: Neuropharmacology Theme	Oral presentations 8: Pharmacogenomics & Clinical Pharmacology Themes
	Room: Eureka Room 1	Room: Eureka Room 2	Room: Eureka Room 3	Room: Courtyard Room 1 & 2
Chairs:	Dr Emma van der Westhuizen, St Vincent's Institute of Medical Research and Michaela Kaoullas, Monash University	Dr Lisa Kouladjian O'Donnell, The University of Sydney and Dr Joel Moore, University of South Australia	Dr Luke Grundy, Flinders Health and Medical Research Institute and A/Prof Celine Valant, Monash Institute of Pharmaceutical Sciences	Lorna Pairman, University of Otago and A/Prof Alison Shield, University of Canberra
14:15 – 14:30	241. Chemoproteomics approaches to deconvolute drug targets for novel anti-malarial candidates A/Prof Darren Creek, Monash University	247. How are deprescribing guidelines disseminated and implemented? Survey of international organisational stakeholders Chun Hei Justin Cheng, The University of Sydney	253. AIM2 inflammasome inhibition improves cognition in a mouse model of vascular dementia Dr Quynh Nhu Dinh, La Trobe University	259. A clinical decision support alert to promote timely laxative prescribing with clozapine Milan Sundermann, University of Otago
14:30 – 14:45	242. Structural analysis and Nanobody development on the relaxin receptor, RXFP1 Prof Ross Bathgate, Florey Institute	248. Patient Focused Pharmacy Practice in Sri Lanka: A Scoping Review Ciera Summers, The University of Queensland	254. Understanding the interplay of STING and TOLLIP in driving secondary injury post-TBI Amelia Fryer, The University of Melbourne	260. Reprogramming histone methylation status as a therapeutic approach for MPNST therapy A/Prof Chung-Ping Liao, Taipei Medical University

14:45 – 15:00	243. Cryo-EM structure of monomeric CXCL12-bound CXCR4 in active state Prof Richard Ye, The Chinese University of Hong Kong - Shenzhen	249. Stakeholders' perspectives of perinatal depression and anxiety screening in primary care: a meta-synthesis Lily Pham, The University of Sydney	255. Functional assay controlling nAChR assembly provides new insights into ADSHE receptor function Lucas David, The University of Sydney	261. "Reaching for a pill" - a qualitative systematic review of gabapentinoid misuse Dr Evan Browne, St Vincent's Hospital, Sydney
15:00 – 15:15	244. Bombesin 3 receptor: a novel target for the deadliest cancer Mariah Stavrou, UNSW Sydney	250. Do type 2 diabetes guidelines consider older adults in the Western Pacific? Darshna Goordeen, Monash University	256. N-linoleyltyrosine improves cognitive dysfunction in obese mice through fatty acid amid hydrolase Prof Sha Liu, Chengdu Medical College	262. Factors contributing to variability in response to follitropins: a systematic review Toni Michael, School of Pharmacy, The University of Sydney
15:15 – 15:30	245. HDX-MS studies on the relaxin receptor, RXFP1 Dr Bradley Hoare, The Florey Institute / The University of Melbourne	251. Where are my mob at? Analysing the representation of Australian Indigenous pharmacists Dr Jared Miles, The University of Queensland	257. Investigating the relationship between CGRP and the calcitonin receptor in the brain Michael Garelja, The University of Otago	263. Optimizing Clinical Impact of Isoniazid Treatment Through Pharmacogenomics and Drug Level Implementation Dr Pajaree Chariyavilaskul, Chulalongkorn University
15:30 – 15:45	246. An intracellular lipid pocket at Frizzled receptors regulates transducer activity Dr Wessel Burger, Walter Eliza Hall Institute of Medical Research	252. Navigating cultural diversity in diabetes care: insights from Australian healthcare professionals Diane Gargya, RMIT University	258. Evaluating Anti-TNF and Small molecules impact on Depression and Anxiety for IBD Irwin Kashani, Flinders University	264. Prolonged off-label antipsychotic therapy and cardiometabolic outcomes in children: a systematic review Ramya Padmavathy Radha Krishnan, The University of Sydney
15:45 – 16:10	Afternoon tea with exhibitors Room: Goldfields Event Space			
15:45 – 16:10	Drug Discovery SIG AGM Room: Eureka Room 1	Drug Disposition & Response SIG AGM Room: Eureka Room 2	Neuropharmacology SIG AGM Room: Eureka Room 3	Toxicology SIG AGM Room: Courtyard Room 1&2
16:15 – 18:15	BELLBERRY New Investigator Award Sponsored by  Bellberry Limited supporting research and ethics		269. Keynote presentation 3: PSA Lecturer To improve is to change – shifts in aged care pharmacist accountability and responsibility Dr Amanda Cross, Monash University	
Chair:	A/Prof Michelle Halls, Monash University		Room: Goldfields Theatre Chair: Dr Vijay Suppiah, The University of South Australia	
16:15 – 16:45	265. Activation and allosteric modulation of the human GLP-1R by small-molecule ligands Xin Zhang, Monash University		APSA AGM	
16:45 – 17:15	266. Molecular pharmacology profiling with BRET-based assays Dr Elizabeth Johnstone, The University of Western Australia		Room: Eureka Room 3	
17:15 – 17:45	267. Updating a multidomain frailty index in older patients in six Australian hospitals Dr Kenji Fujita, Kolling Institute			
17:45 – 18:15	268. Translating evidence to practice: pharmacist-led deprescribing and the SaferMedsNL initiative Dr Justin Turner, Monash University			
18:15 – 19:15		APFP Council Meeting Room: Eureka Room 2		
From 18:30	Student dinner – ticket holders only Venue: Ruby Riviera		Sponsored by	
From 19:00	ASCEPT - APFP – APSA Presidents' Reception (by invitation only) Venue: Cargo Hall			

Tuesday 3 December 2024

07:30 – 17:00	Registration desk open			
	Room: Goldfields Foyer			
08:00 – 08:50	300. Keynote presentation 4: ASCEPT Lecturer From brain peptides to the brain-gut axis - unravelling the science behind obesity to improve outcomes Margaret Morris, UNSW		APSA Emerging Leaders Award	
	Room: Goldfields Theatre		Room: Eureka Room 1	
Chair:	A/Prof Bridin Murnion, St Vincent's Hospital Sydney		A/Prof Lisa Kalisch Ellett, The University of South Australia	
08:00 – 08:15			301. Reduced oral absorption and brain-penetration of caffeine in amyotrophic lateral sclerosis mice Dr Liam Koehn, Monash University	
08:15 – 08:30			302. Risk of aortic aneurysm or dissection following exposure to systemic fluoroquinolone antibiotics Dr Jack Janetzki, The University of South Australia	
08:30 – 08:45			303. "Almost like crickets": Impact of the COVID-19 pandemic on hospital education Dr Sarah Hassan, RMIT	
CONCURRENT SESSION 4				
09:00 – 10:30	ASCEPT Garth McQueen Oral Prize Session Room: Eureka Room 1	Oral presentations 9: Traditional Medicines & Pharmaceutical Sciences Themes Room: Eureka Room 2	Oral presentations 10: Respiratory & Inflammation Theme Room: Eureka Room 3	Oral presentations 11: Pharmacoepidemiology Theme & Tony Smith QUM Award Room: Courtyard Room 1&2
Chairs:	Dr Betty Exintaris, Monash University and Dr Chantal Donovan, The University of Technology Sydney	Dr Thilini Thrimawithana, RMIT University and Dr Aisyah Jaafar, Universiti Teknologi Mara	Dr Daniel Tan, The University of Melbourne and Dr Simone de Luca, RMIT University	Ramya Radha Krishnan, The University of Sydney and Dr Edwin Tan, The University of Sydney
09:00 – 09:15	304. Pharmacological inhibition of interleukin-18 attenuates deoxycorticosterone/salt-induced hypertension, renal inflammation and capillary rarefaction Buddhila Wickramasinghe, Le Trobe University	310. New Approaches to treat organ failure via inhibition of pancreatic enzymes Zijun Lu, Monash University	316. Translational proteomic biomarkers of casein kinase inhibition in macrophages Qianyu Chen, The University of Melbourne	322. Co-designing novel medication management tools for people impacted by dementia during hospitalization Alexander Clough, The University of Sydney
09:15 – 09:30	305. Proteomic analysis of BALF from silicotic Victorian engineered-stone workers reveals secretome landscape Claudia Sim, Monash University	311. Nanosized shikonin: An effective therapeutic agent against sepsis and other inflammation-related disease Dr Yuqing Miao, Shaanxi University of Chinese Medicine	317. Carnosine enhances the cardiovascular benefits of pulmonary rehabilitation on COPD Suleman Almerdasi, RMIT University	323. Impact of in-hospital medication changes on clinical outcomes: the journey and destination Dr Nashwa Masnoon, Kolling Institute, Faculty of Medicine and Health, The University of Sydney and Northern Sydney Local Health District
09:30 – 09:45	306. Feasibility and Acceptability of a Nurse-Pharmacist Post-Discharge Telehealth Heart Failure Service Joshua Bennetts, The University of Newcastle	312. Delivery of siRNA via Bone-targeting LNP efficiently inhibits prostate cancer bone metastasis Dr Yanlun Gu, Peking University First Hospital	318. A novel pro-resolution therapy approach to treat pulmonary arterial hypertension Ting Fu, Monash Institute of Pharmaceutical Sciences	324. DPYD genotype based fluoropyrimidine dosing in variant carriers, and patient clinical outcomes Deirdre Landsberg, The University of South Australia
09:45 – 10:00	307. Characterisation of the pro-atherosclerotic orphan G protein-coupled receptor, GPR146 Brendan Wilkins, UNSW Sydney	313. Kidney-targeted antioxidant salvianolic acid B nanoparticles for acute kidney injury therapy Prof Xiao-Ming Zhu, Macau University of Science and Technology	319. Validation of a novel precision-cut lung slice fibrosis model from TGFβ-overexpressing mice Dr Paris Papagianis, Monash University	325. Glucose lowering medicines utilisation before and after entry into residential aged care Yohanes Wondimkum, University of South Australia
10:00 – 10:15	308. Maternal Thirdhand E-vapour exposure impacts offspring lung health in experimental asthma model Andie Thorpe, The University of Technology Sydney	314. Effect of lipopolysaccharide and anti-inflammatory compounds on murine microglial transporters Ethan Kreutzer, Monash University	320. Sexual Dimorphism in the Sugen-Hypoxia Mouse Model of Pulmonary Arterial Hypertension Chloe Landy, Monash University	326. Consumers' Knowledge and Experiences of Adverse Drug Reaction Reporting in Australia Mohammed Dedefo, The University of South Australia
10:15 – 10:30	309. AT2R agonists C21 and NAc inhibit IPF-fibrogenesis in precision cut lung slices Olivia Young, Monash University	315. Tetrastigma hemsleyanum polysaccharide enhances the anti-cancer efficacy of anti-PD-L1 therapy Prof Jinjian Lu, University of Macau	321. Phosphoproteome changes induced by the CK1δ inhibitor PF670462 in modulating TGF-β-induced fibrogenesis Stephanie Zhang, The University of Melbourne	327. Which care setting are antidepressants initiated on entry to residential aged care? Georgina Hughes, The University of South Australia


10:30 – 11:10	Morning tea with exhibitors Poster presentations: Drug Discovery, Drug Disposition & Response, Innovation & Industry, Neuropharmacology, Pharmacogenomics, Pharmacy Practice, Toxicology, Gastro Urogenital			
	Room: Goldfields Event Space			

CONCURRENT SESSION 5

11:15 – 13:15	Symposium 5: Targeting bacterial ‘superbugs’: From ward to lab Room: Eureka Room 1	Symposium 6: Neuropharmacological Frontiers: Transformational Addiction Therapeutics Room: Eureka Room 2	Symposium 7: Sex differences in cardiovascular disease Room: Eureka Room 3	Symposium 8: Unveiling the next wave of therapies for chronic lung diseases Room: Courtyard Room 1 & 2
Chairs:	Prof Jian Li, Monash University and A/Prof Andrea Kwa, Singapore General Hospital	Prof Kathryn A. Cunningham, John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX and Prof Elena Bagley, Sydney Pharmacy School and Faculty of Medicine and Health	Prof Rebecca Ritchie, Monash Institute of Pharmaceutical Sciences and Dr Maria Jelinic, La Trobe University	Dr Daniel Tran, The University of Melbourne and Prof Jane Bourke, Monash University
11:15 – 11:45	328. Genomics in advancing antimicrobial therapy in the clinical setting Prof Ben Howden, The University of Melbourne	332. Innovative 5-HT_{2A} Receptor Potentiators with Distinct Pharmacological Profiles vs. Psychedelic 5-HT_{2A} R Agonists for Pharmacotherapy of Psychostimulant Use Disorder Prof Kathryn Cunningham, University of Texas Medical Branch	336. Exploring sex differences in various preclinical models of cardiometabolic disease Dr Miles De Blasio, Monash Institute of Pharmaceutical Sciences	340. Cubic Nanostructure and Cholesterol Enhance Lipid Nanoparticle Mediated mRNA Transfection in Macrophages Dr Maggie Zhai, RMIT University
11:45 – 12:15	329. Tailoring antibiotic dosing regimens to maximize efficacy and minimize resistance by use of dynamic <i>in vitro</i> infection models and PK/PD approaches A/Prof Cornelia Landersdorfer, Monash University	333. Opioid Withdrawal Contributes to the Development of Compulsive Drug Use: Prospects for New Pharmacotherapeutics in Opioid Use Disorder Prof Elena Bagley, Sydney Pharmacy School and Faculty of Medicine and Health	337. Unravelling sex differences in the phenotype of pulmonary hypertension to enhance insights into therapeutic approaches Peng-Cheng Wang, Monash University	341. Developing calcaratarin D, a labdane diterpenoid, as therapeutics for chronic lung diseases Prof Fred Wong, National University of Singapore
12:15 – 12:45	330. Structure activity relationships VS. structure-toxicity relations: a key battle in the design of lipopeptide antibiotics Tony Velkov, Monash University	334. The Promise of FKBP51 Antagonists to Mitigate Opioid Relapse Vulnerability Prof John Neumaier, University of Washington School of Medicine and Veterans Administration Puget Sound	338. Resolution of inflammation: sex driving differences Prof Amrita Ahluwalia, The University of London	342. Exploration of CD151 as a therapeutic target in asthma A/Prof Thai Tran, National University of Singapore
12:45 – 13:15	331. Optimising the use of antimicrobials in patients – what have we achieved? A/Prof Andrea Kwa, Singapore General Hospital	335. Serotonin Modulation of Transition to Compulsive Cocaine Intake: Implications for Therapeutics Yue Li, Fudan University	339. Sex differences in susceptibility to ventricular arrhythmias Dr Junko Kurokawa, University of Shizuoka, Shizuoka, Japan	343. Clinical dose estimation for anti CXCR4 i-body-Fc fusion AD-214 for the treatment of fibrotic diseases Dr Jason Lynch, AdAlta Ltd
13:15 – 14:10	Lunch with exhibitors Poster presentations: Drug Discovery, Drug Disposition & Response, Innovation & Industry, Neuropharmacology, Pharmacogenomics, Pharmacy Practice, Toxicology, Gastro Urogenital			
	Room: Goldfields Event Space			

CONCURRENT SESSION 6

14:15 – 15:45	Oral presentations 12: LATE BREAKING ABSTRACTS Room: Eureka Room 1	Oral presentations 13: Education Theme Room: Eureka Room 2	Oral presentations 14: Cardiovascular Theme Room: Eureka Room 3	Oral presentations 15: New Targets and Approaches Room: Courtyard Room 1 & 2
Chairs:	Dr Chiao Xin Lim, RMIT University and Dr Thilini Thrimawithana, RMIT University	A/Prof Tina Hinton, The University of Sydney and A/Prof Carl Schneider, The University of Sydney	Buddhila Wickramasinghe, La Trobe University and A/Prof Bradley Broughton, Monash University	Avanka Gunatilaka, The University of Melbourne and A/Prof Thai Tran, National University of Singapore
14:15 – 14:30	344. Prevalence and risk factors for psychotropic medication use in Australian older adults Trong Hieu (Harry) Le, The University of Sydney	350. Development of Post Graduate Support Programs for Pharmacy Alumni During Internship Matthew West, University of New England	356. The role of cardiomyocyte cavin-1 in cardiac function and development Hui Yi Khoo, The University of Queensland	362. APFP Guest Speaker Innovative strategies in nucleic acid therapeutics: harnessing nanoformulations for precision cancer therapy Prof Yu-Li Lo, National Yang Ming Chiao Tung University
14:30 – 14:45	345. Highly porous inhalable N-acetyl-L-cysteine microparticles developed using spray freeze drying for COPD Prof Shyamal Das, The University of Otago	351. Design, development, and evaluation of continuing professional development modules for community pharmacists Dr Anna-Marie Babey, The University of New England	357. Inhibition of the upregulated phosphodiesterase4D isoforms improves SERCA2a function in diabetic cardiomyopathy Dr Qingtong Wang, QIMR Berghofer Medical Research Institute	
14:45 – 15:00	346. Stakeholders’ views on a virtual pharmacy discharge service for First Nations patients Bushra Haque, The University of Sydney	352. Non-remunerated services provided by community pharmacies: an observational study by pharmacy students Dr Jack Janetzki, University of South Australia	358. Formyl Peptide Receptor Agonism: A Novel Approach for Limiting Abdominal Aortic Aneurysm Jaideep Singh, Monash University	363. LIN28B as a diagnostic and prognostic marker and pharmacological target in Medulloblastoma Dr Iman Azimi, Monash University

15:00 – 15:15	347. Causality, severity and avoidability of adverse drug reactions in children Dr Duaa Gaafar, Royal Children's Hospital	353. VitOOLs VIRTUAL LEARNING PLATFORM for integrated learning in physiology and pharmacology A/Prof Lisa BG Tee, Curtin Medical School	359. Simultaneously targeting RXFP1 and RXFP3 improves stroke outcomes in the photothrombotic model Dr Adriana Knezic, Monash University	364. 3D printed tablets for personalised doses of prednisone using selective laser sintering Zheng Zheng, The University of Queensland
15:15 – 15:30	348. Primary healthcare provider perceptions of a pharmacist-led transition of care service Prof Michael Barras, The University of Queensland	354. Comparing self-regulated learning approaches between school leavers and mature learners Alexandra Steel, Monash University	360. AMPK attenuation of β-adrenergic receptor-induced cardiac injury via phosphorylation of β-arrestin-1-ser330 Prof Han Xiao, Peking University Third Hospital	365. Modulation of host antioxidant proteins' expression by novel antichikungunya virus agents A/Prof Anna Krasilnikova, IMU University
15:30 – 15:45	349. Sexually dimorphic effects of chronic cerebral hypoperfusion in mice Dr Michael De Silva, La Trobe University	355. Harnessing Generative AI for Objective Structured Clinical Examinations Preparation in Pharmacy Education Dr Angelina Lim, Dr Joel Moore & Dr Amna Maze, Monash University	361. Targeting drivers of HFpEF heart failure phenotype in human aortic endothelial cells Dr Anida Velagic, Monash Institute of Pharmaceutical Sciences	366. Using a nano carrier for siRNA delivery to liver sinusoid endothelial cells Laura Westwood, The University of Sydney
15:45 – 16:10	Afternoon tea with exhibitors			
	Room: Goldfields Event Space			
15:45 – 16.10	Pharmacoepidemiology SIG AGM	Respiratory & Inflammation SIG AGM	Cardiovascular SIG AGM	Gastro Urogenital SIG AGM
	Room: Eureka Room 1	Room: Eureka Room 2	Room: Eureka Room 3	Room: Courtyard Room 1&2
CONCURRENT SESSION 7				
16:15 – 17:15	ASCEPT Early Achievement Award for Women Gillian Shenfield Early Educator Award		369. Keynote presentation 5: APSA Lecturer When we say Nothing about us, without us: You say? Prof Faye McMillan, Australian Government Department of Health and Aged Care	
	Room: Eureka Room 1		Room: Goldfields Theatre	
Chair:	A/Prof Elly Djouma, La Trobe University and A/prof Tina Hinton, The University of Sydney		Dr Sarira El-Den, The University of Sydney	
16:15 – 16:45	367. Inhibition of CSF1 receptor activation improves cigarette smoke-induced pulmonary and cognitive outcomes Dr Simone De Luca, RMIT University			
16:45 – 17:15	368. Implementing Educational Escape Rooms in Biomedical Science and Interprofessional Education Dr Iris Lim, Bond University			
17:15 – 18:15	ASCEPT AGM			
	Room: Eureka Room 3			
19:00 – 23:30	Congress dinner		Sponsored by 	
	Venue: Aerial			

07:30 – 14:30	Registration desk open Room: Goldfields Foyer
08:00 – 08:50	400. Keynote presentation 6: ASCEPT Lecturer Message in a model: GPCR allostery from theory to practice Arthur Christopoulos, Monash University Room: Goldfields Theatre
Chair:	A/Prof Nicola Smith, UNSW Sydney
08:50 – 09:40	401. Keynote presentation 7: APSA Medallist Bek's greatest hits: An insight into her playlist for a fun and successful career Prof Rebecca Moles, The University of Sydney Room: Goldfields Theatre
Chair:	A/Prof Lisa Kalisch Ellett, The University of South Australia
09:40 – 10:25	Morning tea with exhibitors Student poster finalists presentations: ASCEPT Neville Percy Prize, ASCEPT Robert Whelan Prize Room: Goldfields Event Space

Sponsored by



CONCURRENT SESSION 8

10:30 – 12:30	Symposium 9: The role of the gut microbiome in cardiometabolic disease Room: Eureka Room 1	Symposium 10: Interindividual variability in disposition and response to infectious disease therapy Room: Eureka Room 2	Symposium 11: AI in Education: Innovations and Applications Room: Eureka Room 3	Symposium 12: Novel inhalable gene and drug delivery strategies to combat respiratory diseases Room: Courtyard Room 1 & 2
Chairs:	Prof Margaret J. Morris, Faculty of Medicine & Health, UNSW and Dr Anida Velagic, Monash Institute of Pharmaceutical Sciences	Prof Nuala Helsby, The University of Auckland and A/Prof David Foster, The University of South Australia	Dr Betty Exintaris and Dr Nilushi Karunaratne, Monash University	A/Prof Lisa Kaminskas, The University of Queensland and Dr Shadab Haque, Monash University-MMIC
10:30 – 11:00	402. Novel insights into the Gut Phageome in Hypertension Dr Antony Vinh, La Trobe University	406. Using real-world data: Can CYP2C19 genotype predict an individuals' response to voriconazole? Dr Sophie Stocker, The University of Sydney	410. Gen AI and pedagogy-approaches, perspectives and strategies Prof Danny Liu and Prof Tim Fawns, Monash University	414. Lentiviral gene therapy and stem cell transplantation in cystic fibrosis: A comparative analysis with CFTR modulator therapy Dr Shafagh Waters, UNSW
11:00 – 11:30	403. Leveraging gut microbes as natural pharmacists to lower blood pressure A/Prof Francine Marques, Monash University	407. Factors which influence pharmacokinetic variability that affect target attainment in patients with drug-resistant bacterial infections in South East Asia A/Prof Cornelia Landersdorfer, Monash University	411. Strategies for designing assessment using and because of Gen AI Angelina Lim and Thao Vu, Monash University	415. Impact of airway surface perturbations and infection on the efficacy of inhaled gene therapy Dr Alexandra McCarron, Adelaide University and the Women's and Childrens Hospital
11:30 – 12:00	404. Alterations in gut microbiota composition, plasma lipids, and brain activity, suggest interconnected pathways influencing malnutrition-associated cognitive and neurodevelopmental changes Prof Justin O'Sullivan, University of Auckland	408. Understanding how drug-pathogen interactions influence variability in drug response Dr Kashyap Patel, GSK	412. Towards an efficient future: The integration of artificial intelligence in education Pranav Runwal, Monash University	416. Inhalable bacteriophage therapy to treat respiratory diseases Prof Hak-Kim Chan, The University of Sydney
12:00 – 12:30	405. Gut microbiota metabolite trimethylamine N-oxide impairs β-cell function and glucose tolerance Prof Pingping Li, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College	409. NAT2 and isoniazid: evidence and road map for implementation Prof Jan-Willem Alffenaar, Sydney School of Pharmacy the University of Sydney	413. Animating basic sciences: AI Crafted Clinical Cases for Deep Learning Engagement Prof Priya Pusparajah, Monash University	417. Next Generation Carrier Particles for Therapeutics Delivery to the Lung: Challenges and Opportunities Clive Prestidge, The University of Sydney

12:30 – 13:10	Lunch with exhibitors Room: Goldfields Event Space
13:10 – 14:00	418. Keynote presentation 8: JPS Lecturer Therapeutic molecules to rectify aberrant RNA splicing Prof Masatoshi Hagjwara, Kyoto University Room: Goldfields Theatre
Chair:	Prof Alastair Stewart, The University of Melbourne
14:00 – 15:00	Awards and congress close Room: Goldfields Event Space
Chair:	Prof Alastair Stewart, The University of Melbourne, A/Prof Bridin Murnion, St Vincent's Hospital Sydney and A/Prof Lisa Kalisch Ellett, The University of South Australia


23rd International Congress of Therapeutic Drug Monitoring & Clinical Toxicology



Singapore 2025

21–24 September
Grand Copthorne Waterfront Hotel
www.iatdmct2025.org



apsa 

APSA 2025 Annual Conference

Sun 7 – Wed 10 December 2025
University of South Australia, City West Campus
Adelaide, South Australia



ASCEPT and Hypertension Australia Joint Scientific Meeting

9–12 December 2025
Adelaide Convention Centre
South Australia

www.ascept-hypertensionau.com.au



20th World Congress of Basic and Clinical Pharmacology 2026

#WCP2026 | wcp2026.org

 **WCP 2026**
12–17 July 2026 Melbourne/Narrm, Australia

 **ASCEPT**
AUSTRALIAN SOCIETY OF
CLINICAL AND EXPERIMENTAL
PHARMACOLOGISTS AND TOXICOLOGISTS

 **TU PHAR**
INTEGRATING KNOWLEDGE AND
THE CLINICAL PHARMACOLOGIST

CELEBRATING 20 YEARS OF EXCELLENCE

Bb Bellberry Limited
supporting research and ethics

Australia's largest reviewer

Human Research Ethics Committees

Working across all phases of clinical and device trials, and social and behavioural studies, our teams support researchers in private, public, academic and government settings Australia-wide.



In 2023 Bellberry supported

43%

of CTN clinical
trials in Australia

Since 2004 we have supported...

1,450+ research organisations

6,180+ investigators and site staff

10,600+ research applications

Our 2023 Clinical Trial Activity Report shows the continued strength of Australia in FIH and Phase 1 trials.

Download the full version of Bellberry CTAR 2023 >



We Care

HREC Excellence
With two key objectives: to protect the welfare of human research participants, and improve the quality, efficiency and effectiveness of research.

Learn more >



We Give

Philanthropic Activities
We support grants for people, projects and direct action initiatives.

Learn more >



We Lead

Research, Policy & Advocacy
We are NHMRC certified, and AAHRPP accredited for excellence and ethically sound processes. The first and only organisation to achieve this in Australia.

Learn more >



We Innovate

Strategic Projects
Development of new products & services to support & improve the excellence of scientific & ethical review and the delivery of research.

Learn more >



For more information about Bellberry and our services >

www.bellberry.com.au

+61 8 8361 3222

bellberry@bellberry.com.au

